晚期结直肠癌靶向治疗进展与出路探讨  

Progress and solution in targeted therapy of advanced colorectal cancer

作　　者：章群[1] 钱晓萍[1] 刘宝瑞[1] 

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心,江苏南京210008

出　　处：《现代肿瘤医学》2013年第11期2589-2593,共5页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81172094)

摘　　要：对结直肠癌中关键信号通路的认识有助于在靶向治疗中确定特异的分子标志物。本综述基于此点进行论述,揭示BRAF、NRAS等多个有潜力的生物学标志在结直肠癌治疗中的地位及意义,系统介绍目前治疗结直肠癌的靶向药物,寻求真正有价值的分子靶标在结直肠癌靶向治疗中的应用价值。The knowledge about key signaling pathways in colorectal tumors has contributed to the identification of specific molecular markers of response to targeted agents.In this review we discuss well-established and potential predictive biomarkers including BRAF,NRAS,and PI3KCA mutations,and PTEN loss are also reviewed personalized cancer medicine in the mCRC scenario seems to be near reality,but many biomarkers in prospective clinical trials is urgently to be validated.

关 键 词：结直肠癌 靶向治疗 表皮生长因子受体信号通路 

分 类 号：R735.3[医药卫生—肿瘤]